IRCM, Institut de recherche en cancérologie de Montpellier, Inserm U1194, INCa_Inserm_DGOS_12553, université de Montpellier, avenue des Apothicaires, 34298 Montpellier cedex 05, France; Département de radiothérapie oncologie, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Université de Lyon, 69000 Lyon, France.
Unité de biométrie, ICM, Institut régional du cancer Montpellier, université de Montpellier, rue Croix-Verte, 34298 Montpellier cedex 05, France.
Cancer Radiother. 2022 Feb-Apr;26(1-2):96-103. doi: 10.1016/j.canrad.2021.11.008. Epub 2021 Dec 22.
The place of personalized treatments is highly increasing in medical and radiation oncology. During the last decades, a huge number of assays have been developed to predict responses of normal tissues and tumours. These tests have not yet been included into daily clinical practice but the recent developments of radiation oncology are paving the way of personalized strategies including the risk of tumour recurrence and normal tissue reactions. Concerning tumor radiosensitivity prediction, no test are currently used, even if the radiosensitivity index and the genome-based model for adjusting radiotherapy dose assays seem the most promising with level II of evidence. Commercial developments are under progress. Concerning normal tissue radiosensitivity prediction, single nucleotide polymorphims of prostate cancer patients and radiation-induced CD8 T-lymphocyte apoptosis breast and prostate assays are of level I of evidence. They can be proposed before the beginning of radiotherapy in order to propose personalized treatments according to both risks of tumour and normal tissue radiosensitivity. Commercial developments are also under way.
个体化治疗在医学和放射肿瘤学中的地位日益提高。在过去的几十年中，已经开发出大量的检测方法来预测正常组织和肿瘤的反应。这些检测尚未纳入日常临床实践，但放射肿瘤学的最新发展正在为个体化策略铺平道路，包括肿瘤复发风险和正常组织反应。关于肿瘤放射敏感性预测，目前尚无检测方法，即使是放射敏感性指数和基于基因组的调整放疗剂量检测模型似乎也最有希望，具有 II 级证据。商业开发正在进行中。关于正常组织放射敏感性预测，前列腺癌患者的单核苷酸多态性和辐射诱导的 CD8 T 淋巴细胞凋亡乳腺癌和前列腺检测具有 I 级证据。它们可以在放射治疗开始前提出，以便根据肿瘤和正常组织放射敏感性的风险提出个体化治疗。商业开发也在进行中。
